Paracetamol in pregnancy: an association, not a verdict
A Danish cohort linked prenatal paracetamol exposure with small differences in girls' ovarian and uterine markers, but it did not establish causation or later fertility harm.
The 60-second version
Prenatal paracetamol exposure was associated with several reproductive-development markers in girls, but the cohort cannot establish causation or future fertility harm.
Key points
- The primary analysis examined 302 infant daughters from a prospective Danish cohort.
- Early exposure was linked with smaller ovarian and uterine volumes; later exposure was linked with fewer visible follicles.
- The study measured developmental proxies, not adult fertility or menopause.
- AMH is anti-Mullerian hormone, not follicle-stimulating hormone.
- Confounding by fever, pain and other treatment indications remains possible.
Verdict. A credible signal for replication and long follow-up, not a basis for alarm or unsupervised medication changes.
Bottom lineWhat the study actually found
In a Danish cohort, prenatal paracetamol exposure was associated with small differences in ovarian volume, uterine volume, follicle count and, in one small subgroup, anti-Mullerian hormone. The findings are worth following up, but they do not establish reproductive harm.
The primary COPANA study was prospective and single-centre. Mothers completed medicine questionnaires every two weeks; 299 supplied a first-trimester urine sample. The infants were examined at a mean age of about 106 days, during the temporary hormone activity known as minipuberty.
NumbersThe measured associations
| Exposure beginning before 17 weeks | Ovarian volume was 0.11 cm3 lower and uterine volume 0.18 cm3 lower than in unexposed girls after adjustment. |
|---|---|
| Exposure beginning at or after 17 weeks | The ultrasound count was 1.05 fewer ovarian follicles on average. |
| Early-only subgroup | AMH was 0.45 standard-deviation units lower; this estimate came from only 22 girls. |
| Confirmatory cohort | Maternal use of paracetamol or NSAIDs was associated with smaller uterine volume at puberty and smaller ovarian volume in adolescence. |
The confidence intervals excluded zero for these selected comparisons, and urine concentrations showed inverse trends with some tissue measurements. Even so, statistical significance does not tell us whether a difference is clinically important.
BoundaryWhat the study cannot tell us
- No causation: fever, infection, pain and other reasons for taking medicine may differ between exposed and unexposed families.
- No adult fertility outcome: the study did not measure time to pregnancy, infertility, premature ovarian insufficiency or menopause.
- Limited generalizability: the main cohort came from one hospital and selected healthy singleton pregnancies of Caucasian origin.
- Imperfect replication: the second cohort used a broader self-reported exposure that combined paracetamol with other pain medicines.
Ultrasound does not identify every infant ovary, and normal ovarian size and follicle counts vary widely during infancy. The authors themselves say the long-term clinical relevance is uncertain.
ContextWhy the signal is still worth studying
Experimental animal and fetal-tissue studies have reported effects on germ-cell development, which gives the association biological plausibility. But evidence from animals or cells cannot prove the same outcome at ordinary human doses.
A developmental marker is a clue for longer follow-up, not a diagnosis of future infertility.
Practical stepDo not change treatment on your own
Untreated fever and pain can also matter during pregnancy. The appropriate response is not abrupt avoidance: use medication only when needed, follow professional advice on dose and duration, and discuss persistent symptoms or alternatives with a qualified clinician.